Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline

Rhea-AI Summary

Caris Life Sciences announced a strategic research partnership with Incyte Corporation on March 7, 2023, to enhance precision medicine approaches for Incyte's oncology pipeline. This partnership leverages Caris' advanced molecular science solutions, including comprehensive profiling and AI capabilities, to improve patient outcomes. Initially focusing on two therapeutic programs, Incyte has the option to expand to four. This collaboration aims to optimize clinical trial strategies and discover novel biomarkers, reinforcing Incyte's commitment to developing innovative cancer treatments.

Positive

• Strategic partnership with Caris Life Sciences to enhance precision medicine for oncology.
• Access to advanced molecular profiling and AI analytics to improve patient outcomes.
• Initial focus on two therapeutic programs with potential to expand to four.
• Optimizes clinical trial enrollment and strategies, potentially increasing success rates.

Negative

• None.

IRVING, Texas, March 7, 2023 /PRNewswire/ -- Caris Life Sciences^®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced a strategic research partnership with Incyte Corporation (NASDAQ:INCY) to augment precision medicine approaches for Incyte's oncology pipeline.

This partnership with Incyte will leverage Caris' leading molecular science and technology solutions

Caris' unique platform combines data from whole exome sequencing, whole transcriptome sequencing, protein analysis, and proprietary AI models and signatures to improve patient outcomes through advancement of personalized medicine. The partnership will apply Caris' data and analytics tools, comprehensive molecular tissue and liquid profiling services, and clinical trial enrollment program capabilities across two therapeutic programs initially, with the option for Incyte to expand to four total programs.

"This partnership with Incyte will leverage Caris' leading molecular science and technology solutions to support Incyte's oncology research and development efforts," said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris Life Sciences. "The aggregate strength of our platform, which provides patient level DNA and RNA data both in tissue and  blood, may help to better identify and predict patient response to therapy, which in turn may accelerate clinical trial enrollment, optimize clinical positioning and potentially enhance technical and regulatory success." 

Under the terms of the agreement, Incyte will leverage Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for its oncology programs. For drug candidates developed under the collaboration, patients enrolled in Incyte-led clinical trials will undergo longitudinal testing with Caris' comprehensive tissue and liquid molecular profiling assays. Incyte will also leverage Caris' biomarker-driven patient selection for clinical trials including options to partner on developing companion diagnostics for programs in the partnership.

"Incyte is committed to identifying new treatments for cancer patients using approaches exploring both single agents and combinations of targeted therapies and immunotherapies in areas of high unmet medical need," said Jeff Jackson, Ph.D., Vice President, Translational Sciences at Incyte. "Our partnership with Caris will bring a comprehensive suite of precision medicine capabilities to augment Incyte's success in developing key programs in our robust oncology portfolio."

About Caris Life Sciences
Caris Life Sciences^® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.

With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. The company's latest advancement, Caris Assure™, is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributors provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on LinkedIn.

Caris Life Sciences Media Contact:
Lisa Burgner
corpcomm@carisls.com
214.294.5606

Caris Life Sciences Business Development Contact:
Brian Lamon, Ph.D.
Chief Business Officer, Head of BioPharma Business Development
blamon@carisls.com
609.955.8883

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-and-incyte-enter-into-broad-precision-medicine-partnership-to-advance-incytes-oncology-pipeline-301764183.html

SOURCE Caris Life Sciences

FAQ

What is the partnership between Incyte and Caris Life Sciences about?

The partnership focuses on enhancing precision medicine approaches for Incyte's oncology pipeline through advanced molecular profiling and AI capabilities.

What date was the partnership between Incyte and Caris announced?

The partnership was announced on March 7, 2023.

How many therapeutic programs will Incyte and Caris initially focus on?

They will initially focus on two therapeutic programs, with the option to expand to four.

What is the main goal of the Incyte and Caris partnership?

The main goal is to optimize clinical trial strategies and discover novel biomarkers to improve cancer treatment outcomes.

How will the partnership impact Incyte's oncology pipeline?

The partnership aims to enhance Incyte's oncology pipeline by leveraging Caris' data insights and analytics for better patient selection and clinical trial positioning.